Drug Trial Radar · NCT06603844
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
51
Actual
Start
Dec 4, 2024
Primary completion
Jan 30, 2026
Study completion Jan 30, 2026
Sponsor
- Lead sponsor
- Corbus Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety, blood concentrations and treatment effect of CRB-601 in combination with immunotherapy in patients who have advanced solid tumors (cancer) and have exhausted other therapeutic options.CRB-601 targets a protein called avb8 integrin which is expressed by some cancers and not others. This study will focus on tumor types which are know to highly or moderately express this protein. Researchers will evaluate the side effects caused by treatment, levels of CRB-601 in the blood, and the effect on the participant cancer. This will help researchers understand the right dose of CRB-601 to use for treatment and whether it is an effective treatment to combine with standard of care treatments such as immunotherapy. It will also help the researchers understand whether combining CRB-601 with standard-of-care immunotherapy and immune-priming radiotherapy is a safe and effective approach to treat cancer. Participants in the study will receive CRB-601 via an infusion every two weeks either alone or in combination with immunotherapy. There will be assessments to check on the participants general health status (including blood tests) and adverse effects. Participants will also receive regular CT or MRI scans to evaluate the effect of CRB-601 on their cancer. Participants will continue to visit the clinic every two weeks while they are receiving benefit from treatment. If their cancer progresses, participants will be asked to continue to be followed-up by the researchers to understand long-term outcomes, even if they receive other treatments.
Conditions
- Solid Tumor
Interventions
CRB-601 monoclonal antibodyDrug
CRB-601
Anti-PD-1 monoclonal antibodyDrug
Anti-PD(L)-1 used as per label
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurance of Dose-limiting toxicitiesTime frame: 28 days
- Characterize the safety of CRB-601 in combination anti-PD(L)1 therapyTime frame: 6 months
- To evaluate the efficacy of CRB-601 in terms of DCR when administered in combination with anti-PD(L)-1Time frame: 6 months
Locations
26 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
SCRI - Arizona Oncology Associates
Tucson, Arizona
The University of Arizona Cancer Center
Tucson, Arizona
UC San Diego Health - Moores Cancer Center
La Jolla, California
Cedars-Sinai Medical Center
Los Angeles, California
University of California San Francisco
San Francisco, California
SCRI - Rocky Mountain Cancer Centers
Denver, Colorado
Advent Health Oncology Hematology
Orlando, Florida
SCRI- Lake Nona DDU
Orlando, Florida
University of Chicago
Chicago, Illinois
SCRI - Minnesota Oncology Hematology
Maple Grove, Minnesota
Nebraska Hematology Oncology
Lincoln, Nebraska
Duke Cancer Center
Durham, North Carolina
University Hospital of Cleveland (Case Western)
Cleveland, Ohio
SCRI - OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma
SCRI - Nashville
Nashville, Tennessee
START - San Antonio
San Antonio, Texas
SCRI- Texas Oncology
Tyler, Texas
SCRI - Virginia Cancer Specialists
Fairfax, Virginia
SCRI - Oncology and Hematology Associates of Southwest Virginia
Roanoke, Virginia
Edinburgh Cancer Research Centre
Edinburgh, United Kingdom
Beatson West of Scotland Cancer Center
Glasgow, United Kingdom
Guys and St Thomas NHS Foundation Trust
London, United Kingdom
The Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, Tyne and Wear, United Kingdom
The Christie NHS Foundation Trust - Christie Hospital
Manchester, United Kingdom, United Kingdom
The Clatterbridge Cancer Center NHS Foundation Trust
Birkenhead, Wirral, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.